Nurix Therapeutics, Inc. (NRIX) has 12 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 4 sales totalling $757K. Most recent filing: Sept. 2, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 2, 2026 | Ring Christine Chief Legal Officer | $98,610 | 17,361 | 0% | Yes | |
|
|
||||||
| Sept. 1, 2026 | Hansen Gwenn Chief Scientific Officer | $34,282 | 4,356 | 0% | Yes | |
|
|
||||||
| Aug. 5, 2026 | Hansen Gwenn Chief Scientific Officer | $100,798 | 13,068 | 0% | Yes | |
|
|
||||||
| Aug. 5, 2026 filed Aug. 4, 2026 | Hansen Gwenn Chief Scientific Officer | −$100,142 | 4,111 | −3% | Yes | |
|
|
||||||
| Aug. 4, 2026 | van Houte Hans Chief Financial Officer | −$115,989 | 4,761 | −11% | Yes | |
|
|
||||||
Showing the 5 most recent of 12 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free